Search Results
Oct 06, 2025, 18:05 ET Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
[5] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. [6] Morris
More news about: BioArctic
Oct 06, 2025, 18:02 ET Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
[5] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. [6] Morris
More news about: BioArctic
Oct 06, 2025, 16:30 ET Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
doi:10.1038/s41467-021-23507-z Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. Morris JC. Neurology. 1993;43(11):2412-4.
More news about: Eisai Inc.
Oct 02, 2025, 09:00 ET LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
Rao SV, O'Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862. Vinci P, Di Girolamo FG, Panizon E, et al. Int J Environ Res Public Health. 2023;20(18):6721. Published 2023 Sep 6. doi:10.3390/ijerph2018672. Stein EA, Wasserman SM, Dias
More news about: Amgen
Oct 02, 2025, 03:23 ET Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
Disorders 2025. Burns MR, McFarland NR. Neurotherapeutics. 2020;17:1582–1602. Mészáros L, et al. Int J Mol Sci. 2020;21:2775. Kidwell KM, et al. Orphanet J Rare Dis. 2022 May 7;17(1):186 Garczarek
More news about: H. Lundbeck A/S
Oct 02, 2025, 03:20 ET Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
Disorders 2025. Burns MR, McFarland NR. Neurotherapeutics. 2020;17:1582–1602. Mészáros L, et al. Int J Mol Sci. 2020;21:2775. Kidwell KM, et al. Orphanet J Rare Dis. 2022 May 7;17(1):186 Garczarek
More news about: H. Lundbeck A/S
Sep 29, 2025, 02:38 ET Leqembi® approved for IV maintenance treatment in China
[iv] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. This information was brought to you by
More news about: BioArctic
Sep 29, 2025, 02:34 ET Leqembi® approved for IV maintenance treatment in China
[iv] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. This information was brought to you by
More news about: BioArctic
Sep 25, 2025, 16:30 ET Zimmer Biomet Announces Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System
A V. Three-Year Results with a Ringless Third- Generation Porous Plasma Sprayed Acetabular Component in Primary Total Hip Arthroplasty. Surg Technol Int [Internet]. 2017 Jan; 30:295—299. Available from:
More news about: Zimmer Biomet Holdings, Inc.
Sep 24, 2025, 06:26 ET The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
14;43(39):3925-3946[6] Vinci P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721[7] Novartis-commissioned online survey, March 17–30, 2025;
More news about: Global Heart Hub & Novartis
Sep 24, 2025, 06:23 ET 隱藏的基因威脅：全球五分之一人口面臨心血管疾病風險--專家呼籲應對脂蛋白(a) 升高
14;43(39):3925-3946[6] Vinci P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721[7] Novartis-commissioned online survey, March 17–30, 2025;
More news about: Global Heart Hub & Novartis
Sep 24, 2025, 06:21 ET 심혈관 질환 발생 위험을 야기하는 유전적 위험 인자: 글로벌 전문가들, Lp(a)에 대한 대응 촉구
14;43(39):3925-3946[6] Vinci P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721[7] Novartis-commissioned online survey, March 17–30, 2025;
More news about: Global Heart Hub & Novartis
Sep 22, 2025, 09:07 ET BANC3 Secures Defense Contract to Develop Wideband Non-blocking RF Switch Matrix for Next-Generation Electronic Warfare
modernization efforts. Opportunities include integration into U.S. Navy and Air Force initiatives such as the P-8 Poseidon SIGINT upgrade, the MQ-4 Triton Multi-INT upgrade, and AFSPECWAR Tactical Air Control Party (TACP) missions. In addition, the system aligns with the Pentagon's broader Joint All-Domain Command
More news about: BANC3
Sep 16, 2025, 19:31 ET Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid
More news about: Eisai Inc.
Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
on Mental Illness.Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125© Johnson & Johnson 2025. All rights reserved.
More news about: Johnson & Johnson